On this page
- Why the ankle is a different problem
- What has been studied in the ankle
- Talar cartilage lesions versus whole-joint arthritis
- Disease modification, and whether anything achieves it
- How it is given
- What a reasonable expectation looks like
- Who is least likely to benefit
- Risks worth weighing
- Questions to ask before booking
- Frequently asked questions
- Requesting a medical evaluation
Ankle arthritis is not knee arthritis with a different postcode. It usually follows an injury rather than decades of wear, it affects a smaller and differently shaped cartilage surface, and it has been studied far less. Stem cell treatment for ankle osteoarthritis is offered widely in Thailand on the strength of knee data that was never collected in the ankle.
Why the ankle is a different problem
Most knee arthritis is primary — it develops over years without a single identifiable cause. Most ankle arthritis is post-traumatic, following a fracture or repeated sprains that left the joint incongruent.
That changes what a treatment would have to do. In a knee, the target is diffuse cartilage loss across a large surface. In an ankle, it is often a focal defect in the talar dome, sometimes with the underlying bone involved, in a joint carrying more load per square centimetre than any other in the body.
The cartilage itself differs too: thinner, stiffer, and more resistant to the degenerative changes seen elsewhere — which is why ankles rarely develop arthritis without an injury first.
Anyone quoting knee trial results at you for an ankle is quoting the wrong trials. See knee osteoarthritis for what that evidence actually covers.
What has been studied in the ankle
A systematic review has gathered the work on adipose-derived cells across ankle pathologies — Adipose-derived stem cells applied to ankle pathologies: a systematic review.
A second review looked specifically at non-surgical options for ankle cartilage, splitting cellular from acellular approaches — Conservative Treatment for Ankle Cartilage: Cellular and Acellular Therapies.
Both are reviews of small studies. A systematic review inherits the quality of what it reviews, and pooling ten small uncontrolled series does not produce the evidential weight of one good randomised trial.
Talar cartilage lesions versus whole-joint arthritis
Much of the ankle literature is about osteochondral lesions of the talus — a discrete hole in the cartilage and often the bone beneath it, usually in a younger patient after an injury.
That is a surgical problem with established surgical answers, and cells are typically studied as an addition to surgery rather than as an alternative to it. Marrow stimulation, grafting and scaffold techniques are the comparators.
Established, diffuse ankle arthritis in an older patient is a different condition with different options, and the cartilage-lesion literature does not speak to it. Reading one as the other is the most common mistake made on this topic.
Platelet-rich plasma has been reviewed in talar cartilage repair specifically — Platelet-rich plasma treatment for talar cartilage repair: a systematic review and meta-analysis — and is frequently sold under a stem cell heading. See PRP therapy.
Disease modification, and whether anything achieves it
The question behind every regenerative injection is whether it changes the disease or only the symptoms. A review addressed that directly across biologic injections — Biologic injections for osteoarthritis and articular cartilage damage: can we modify disease? — and the question mark in the title is not decoration.
Symptom improvement is measurable and worth having. It is also what a placebo injection into a painful joint produces at a rate that surprises people, which is exactly why controlled trials matter more here than testimonials.
Structural change is measured on imaging and is much harder to demonstrate. Where it has been looked for in joints, it has usually been small, inconsistent, or absent.
How it is given
Intra-articular injection into the ankle, usually with ultrasound or fluoroscopic guidance because the joint space is narrow and a blind injection misses more often than in the knee.
Cells may be adipose-derived, marrow-derived or from donated umbilical cord tissue. Those are not interchangeable and the choice should be explained — mesenchymal stem cell therapy sets out the differences.
Where cells are your own, there is a harvest procedure first, with its own recovery and its own risks. That is often skipped over in a quotation.
What a reasonable expectation looks like
Possible reduction in pain and improvement in function over months, on evidence that is thin for this joint specifically.
No reliable basis to expect a reshaped joint, a reversed injury, or a deferred fusion or replacement. If someone offers those, ask which ankle trial they are quoting.
A treatment that does not work still costs the flight, the fee and the recovery time. That is the real downside, and it is not small.
Who is least likely to benefit
Bone-on-bone arthritis with the joint space gone. There is no cartilage left to influence and no published basis for expecting cells to rebuild it.
Significant malalignment. If the ankle sits crooked after a badly healed fracture, the mechanical problem drives the cartilage loss and an injection does not touch the mechanics.
Active infection, uncontrolled inflammatory arthritis, or a joint already listed for fusion or replacement on solid grounds.
Risks worth weighing
Joint infection after any injection — rare, serious, and requiring urgent treatment if the ankle becomes hot, swollen and increasingly painful over days rather than settling.
Transient pain and swelling for several days afterwards is common and expected.
Harvest-site problems where cells are taken from your own fat or marrow, and the ordinary risks of sedation where it is used. Documented adverse events covers what has been reported in the wider sector.
Questions to ask before booking
- Is this a focal talar lesion or established arthritis, and which trials apply to mine?
- Which cell source, what dose, and on what basis was that dose chosen?
- Is the injection image-guided?
- What is the plan if there is no improvement at six months?
- What does the total cost include, and what does it not?
The patient journey describes how an assessment should run, and treatment cost in Thailand covers what drives the price.
Frequently asked questions
Does the knee evidence apply to my ankle?
No. Different joint, different cartilage, usually a different cause. The ankle has its own small literature and it is much weaker.
Can this help me avoid an ankle fusion?
No published trial has tested that. Anyone presenting it as an alternative to fusion is going well beyond the evidence.
Is PRP the same thing?
No, though it is often sold alongside or as part of the same package. Platelet-rich plasma contains no stem cells.
How many injections would I need?
There is no established ankle protocol. Dosing schedules in this field vary widely between trials and are rarely justified from data.
Will an MRI show whether it worked?
Imaging may show change, but symptom improvement and structural change do not reliably track together, and small studies rarely image at all.
Is it worth flying to Thailand for?
That depends on what you are told to expect. If the expectation is honest — possible symptom relief on thin evidence — it is a decision you can weigh. If it is framed as repair, the framing is wrong.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.